| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
dean17 • Stockfuse Continuum (US) • Mar 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
WSK • OLD|Aalto Investment Management Game (Spring 2020) • Jan 2020
Portfolio consists of 20 biotechnology/pharmaceutical corporations' stocks. Equal weighting | Passive buy and hold strategy, long term.
Novo Nordisk A/S is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. Novo Nordisk has experience and capabilities to develop even further. It has a low beta of 0.59 and its stock price have grown steadily over the past couple years.
Buttonwood • CSM Best of the Best (80 stocks) • Nov 2019
Closing position
bpgelfand1 • Stockfuse Continuum (US) • Oct 2019
I want to invest in a pharmaceutical company.
group39 • OLD|Aalto Investment Management Game (Spring 2019) • Jan 2019
This transaction suits our strategy. Long position. Good historical returns. Well diversified. A leader in healthcare.
ShortTheVIXNow • OLD|Aalto Investment Management Game (Spring 2019) • Jan 2019
This transaction follows our fund strategy: passively investing in the 25 largest firms in the healthcare sector (NYSE & NASDAQ) by market capitalization. Equal nominal weighing is used in all transactions. For more information: refer to the fund brochure.